

## ABSTRACT

The invention relates to novel proteins with novel integrin and I domain activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of integrin related disorders.

5

106070 "T94060

Table 1. Computationally designed mutants<sup>a</sup>

Table 1

	WT	ido1q	ido1r	ido2r	jlm2r
Backbone	Energy <sup>b</sup>				
lido	-1037	-1145	-1138	-1116	-678
ljlm	-1059	+82758	-840	-1000	-1086
Position	Residues				
139	I	-	-	V	-
153	M	-	-	A	-
156	F	L	W	-	-
157	V	-	-	I	-
160	V	I	-	-	-
199	V	I	I	I	-
215	I	L	L	-	V
219	V	-	-	-	I
223	F	-	-	-	L
238	V	F	F	I	I
239	V	L	L	L	-
240	I	L	L	-	-
259	A	L	L	-	-
269	I	L	-	-	-
271	V	F	-	-	-
287	I	V	V	V	-
299	V	A	I	I	-
308	I	V	-	-	-

<sup>a</sup> Mutants are named according to the structure that was stabilized (ido or jlm), the solvation potential used (1 or 2) and the definition of core residues (q or r).

<sup>b</sup> The lowest energy rotamer configuration was calculated for each sequence in the lido structure, and cross-calculated in the ljlm structure, using both solvent potentials; all 50 core residues were used in order to make the q and r energies comparable. Results are shown for solvent potential 1 and were similar for potential 2. A severe clash of the side-chain of F271

with the backbone caused the high energy of the 1q sequence in the 1jlm structure; no movement of the backbone is allowed by the design method.

09902481.070904

Table 1